Biogen Inc. (biib)
BIIB Financials
| Trailing P/E | 39.30 |
| Forward P/E | 13.76 |
| Price/Sales | 3.35 |
| Price/Book | 1.78 |
| Market cap | $33.62B |
| Avg volume | 1101204.0 |
| Shares outstanding | 147753998.0 |
Start Free — open BIIB in Vest Terminal
Access live data, filings, ownership, and analysis for Biogen Inc..
Biogen Inc. FAQ
What does Biogen Inc. (BIIB) do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYC…
What is BIIB's P/E ratio?
Biogen Inc. has a trailing P/E of 39.30× based on publicly available market data.
Does BIIB pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is BIIB in?
Biogen Inc. is classified in Healthcare (Drug Manufacturers - General) on NMS.
What is BIIB's market capitalization?
Approximate market cap: $33.62B.
What are the main risks for BIIB?
Key risks include elevated valuation, among factors on this page.
What are the strengths of BIIB?
Potential positives include gross margin of 78.3% supports competitive unit economics, positive free cash flow ($1.27b).
Where can I get analyst estimates for BIIB?
Public analyst price targets and consensus for Biogen Inc. are on the free /stocks/biib/estimates page. Deeper estimate history and models are available in Vest Terminal.